BCMA-directed mRNA CAR-T (Descartes-08) in generalized myasthenia gravis: placebo-controlled phase 2b trial showed durable clinical efficacy without lymphodepletion and without decline in vaccine-specific antibodies or hypogammaglobulinemia

BCMA-directed mRNA CAR-T (Descartes-08) in generalized myasthenia gravis: placebo-controlled phase 2b trial showed durable clinical efficacy without lymphodepletion and without decline in vaccine-specific antibodies or hypogammaglobulinemia - Notizie Vera Health